Literature DB >> 27003435

Premixed insulin regimens in type 2 diabetes: pros.

Maria Ida Maiorino1, Giuseppe Bellastella2, Katherine Esposito2, Dario Giugliano3.   

Abstract

Because of the increasing prevalence of type 2 diabetes, the need to intensify treatment to manage hyperglycemia is expanding. Premixed insulin regimens were designed to maximize patient convenience and reduce the number of daily injections required by providing both rapid-acting and intermediate-acting components in one formulation. Although the basal bolus insulin regimen is considered by many as "the golden standard" in reaching goals of glycemic control, proper use of intensified insulin regimens, such as basal bolus or premixed, will result in similar HbA1c reduction, hypoglycemic events, and weight gain. At the same number of daily insulin injections (2 shots/day), the premixed regimen is associated with a significant 0.2 % HbA1c decrease, as compared with the basal plus regimen (one shot of long-acting plus one shot of short-acting insulin). The choice of insulin regimen should consider the preferences, and resources of the individual and the family for adapting treatment to the patient needs. At last, the process of insulin initiation and intensification in type 2 diabetes must be carried out in the context of patient safety, minimizing the risk of hypoglycemia, weight gain, and injection burden.

Entities:  

Keywords:  Basal bolus insulin regimen; Basal plus insulin regimen; Premixed insulin regimen; Type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27003435     DOI: 10.1007/s12020-016-0917-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Type 2 diabetes: multimodal treatment of a complex disease.

Authors:  Dimitri J Pournaras; Carel W le Roux
Journal:  Lancet       Date:  2015-09-05       Impact factor: 79.321

2.  Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts.

Authors:  Dario Giugliano; Mariusz Tracz; Sanjiv Shah; Alfonso Calle-Pascual; Cristina Mistodie; Rui Duarte; Ramazan Sari; Vincent Woo; Alina O Jiletcovici; Jürgen Deinhard; Simone A Wille; Jacek Kiljanski
Journal:  Diabetes Care       Date:  2013-10-29       Impact factor: 19.112

3.  Why is there no generic insulin? Historical origins of a modern problem.

Authors:  Jeremy A Greene; Kevin R Riggs
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

4.  Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study.

Authors:  Edward W Gregg; Xiaohui Zhuo; Yiling J Cheng; Ann L Albright; K M Venkat Narayan; Theodore J Thompson
Journal:  Lancet Diabetes Endocrinol       Date:  2014-08-12       Impact factor: 32.069

5.  A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care.

Authors:  B T Blak; H T Smith; M Hards; A Maguire; V Gimeno
Journal:  Diabet Med       Date:  2012-08       Impact factor: 4.359

6.  Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.

Authors:  C Mathieu; F Storms; J Tits; T F Veneman; I M Colin
Journal:  Acta Clin Belg       Date:  2013 Jan-Feb       Impact factor: 1.264

Review 7.  Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Authors:  C Wang; J Mamza; I Idris
Journal:  Diabet Med       Date:  2015-02-13       Impact factor: 4.359

Review 8.  Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review.

Authors:  Dario Giugliano; Maria Ida Maiorino; Giusppe Bellastella; Paolo Chiodini; Katherine Esposito
Journal:  Diabetes Res Clin Pract       Date:  2010-09-06       Impact factor: 5.602

9.  Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?

Authors:  Dario Giugliano; Maria Ida Maiorino; Giuseppe Bellastella; Michela Petrizzo; Antonio Ceriello; Stefano Genovese; Katherine Esposito
Journal:  Endocrine       Date:  2015-02-12       Impact factor: 3.633

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

View more
  1 in total

1.  Glucose-activatable insulin delivery with charge-conversional polyelectrolyte multilayers for diabetes care.

Authors:  Yanguang Yang; Xiangqian Wang; Xiaopeng Yuan; Qiwei Zhu; Shusen Chen; Donglin Xia
Journal:  Front Bioeng Biotechnol       Date:  2022-09-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.